Editorial: pharmacodynamics of potassium-competitive acid blockers: comparing apples with apples-and with oranges
- PMID: 33333612
- DOI: 10.1111/apt.16140
Editorial: pharmacodynamics of potassium-competitive acid blockers: comparing apples with apples-and with oranges
Comment in
-
Editorial: pharmacodynamics of potassium-competitive acid blockers: comparing apples with apples - and with oranges. Authors' reply.Aliment Pharmacol Ther. 2021 Jan;53(1):192-193. doi: 10.1111/apt.16165. Aliment Pharmacol Ther. 2021. PMID: 33333599 No abstract available.
Comment on
-
Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.Aliment Pharmacol Ther. 2020 Dec;52(11-12):1640-1647. doi: 10.1111/apt.16121. Epub 2020 Nov 1. Aliment Pharmacol Ther. 2020. PMID: 33131095 Clinical Trial.
References
REFERENCES
-
- Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048-1059.
-
- Sakurai Y, Mori Y, Okamoto A, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label crossover study. Aliment Pharmacol Ther. 2015;42:719-730.
-
- Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685-695.
-
- Cho YK, Choi M-G, Choi SC, et al. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Therap. 2020;52:789-797.
-
- Sunwoo J, Ji SC, Oh J, et al. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Aliment Pharmacol Ther. 2020;52:1640-1647.